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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.010Excessive neutrophil migration across the pulmonary endothelium into the lung and release of oxidants
and proteases are key elements in pathogenesis of acute lung injury. Previously, we identiﬁed protein
kinase C-delta (PKCd) as an important regulator of proinﬂammatory signaling in human neutrophils and
demonstrated that intratracheal instillation of a TAT-conjugated PKCd inhibitory peptide (PKCd-TAT) is
lung protective in a rat model of sepsis-induced indirect pulmonary injury (cecal ligation and puncture).
In the present study, intratracheal instillation of this PKCd inhibitor resulted in peptide distribution
throughout the lung parenchyma and pulmonary endothelium and decreased neutrophil inﬂux, with
concomitant attenuation of sepsis-induced endothelial ICAM-1 and VCAM-1 expression in this model. To
further delineate the role of PKCd in regulating neutrophil migration, we used an in vitro transmigration
model with human pulmonary microvascular endothelial cells (PMVECs). Consistent with in vivo ﬁndings,
inhibition of PMVEC PKCd decreased IL-1bemediated neutrophil transmigration. PKCd regulation was
stimulus-dependent; PKCd was required for transmigration mediated by IL-1b and fMLP (integrin-
dependent), but not IL-8 (integrin-independent). PKCd was essential for IL-1bemediated neutrophil
adherence and NF-kBedependent expression of ICAM-1 and VCAM-1. In PMVECs, IL-1bemediated
production of ROS and activation of redox-sensitive NF-kB were PKCd dependent, suggesting an up-
stream signaling role. Thus, PKCd has an important role in regulating neutrophileendothelial cell in-
teractions and recruitment to the inﬂamed lung. (Am J Pathol 2014, 184: 200e213; http://dx.doi.org/
10.1016/j.ajpath.2013.09.010)Supported in part by NIH grants RO1 HL111552 (L.E.K.), R01 DK064344
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D.J.K., University of Maryland School of Medicine, Baltimore, MD.Sepsis and sepsis-induced lung injury are among the leading
causes of death in intensive care units, resulting in more than
200,000 deaths per year in the United States.1 The lung is the
organ most often affected; lung injury results in pulmonary
dysfunction, which can develop into acute lung injury or the
more severe acute respiratory distress syndrome (ARDS).2e4
Sepsis is characterized by an intense inﬂammatory response
leading to excessive neutrophil inﬁltration of the lungs,
producing tissue damage.2,5e7 Although neutrophils are cri-
tical to host defense against pathogens, neutrophil dysregu-
lation has a critical role in the early course of lung injury and
development of respiratory failure, through release of pro-
teases and oxygen radicals that damage lung tissue and result
in lung edema and impaired gas exchange.5e8stigative Pathology.
.ARDS can develop from direct pulmonary sepsis (eg,
pneumonia) or nonpulmonary sepsis (eg, intra-abdominal
sepsis). Although both lead to common pulmonary alterations
associated with ARDS, the underlying pathophysiology may
be distinct.9e12 During pulmonary infections, there is direct
PKCd Regulates Neutrophil Migrationinteraction with pathogens and pathogen-associated molecular
patterns involving lung epithelium and alveolar macrophages
that generate proinﬂammatory mediators and chemotactic gra-
dients which recruit neutrophils and other immune cells to the
site of pulmonary infection. Conversely, indirect pulmonary
injury arises from proinﬂammatory mediators released from
remote infectious foci, leading to a systemic inﬂammatory
response, activation of circulating neutrophils, and increased
global vascular endothelial permeability.9e12
To date, therapeutic approaches to the treatment of sepsis-
induced acute lung injury or ARDS have been largely sup-
portive, and no speciﬁc pharmacological therapies are
available to protect the lung from neutrophil-mediated
damage.13e15 Potential therapeutic target sites include local
control of the response of the lung to systemic inﬂammation,
as well as direct modulation of neutrophil migration and
activation. The inﬂammatory response involves multiple
overlapping and redundant mechanisms, which in turn
involve numerous cell types and signaling pathways. Recent
research efforts have focused on common control points in
signaling that are activated by diverse signals. Several control
points are appropriate for drug targeting, and protein kinase
inhibitors have become a major focus for the development of
anti-inﬂammatory drugs.16e18
Our research group identiﬁed the protein kinase C isotype
delta (PKCd) as a critical regulator of the inﬂammatory response
and an important signal transducer of multiple signaling
pathways.19e24 PKCd is activated by proinﬂammatory media-
tors involved in the septic response (including pathogen-
associated molecular patterns such as LPS and the bacterial
peptide fMLP), aswell as proinﬂammatory cytokines (including
TNF-a and IL-1b).20,25 Moreover, PKCd is activated in the
lungs of a rat model of sepsis-induced indirect lung injury.24
Studies with PKCd-deﬁcient mice and PKCd inhibitors have
indicated a role for PKCd in regulating immune cell trafﬁcking
to the lung in response to pulmonary inﬂammation triggered by
asbestos exposure, LPS, strokeereperfusion injury, or pan-
creatitis.26e29 Recently, our research group demonstrated that
targeted inhibition of pulmonary PKCdwith a peptide inhibitor
has an anti-inﬂammatory and lung-protective effect in a rat
model of sepsis-induced lung injury.24 PKCd is an important
regulator of both neutrophil and endothelial and epithelial
proinﬂammatory signaling.20e23,25,30,31 However, the mecha-
nism by which PKCd modulates neutrophil-mediated lung
injury is not known.
The endothelium plays an integral role in the pathogen-
esis of sepsis-induced lung injury by facilitating the
recruitment and activation of neutrophils through the pro-
duction of chemokines and cytokines and the expression of
adhesion molecules.2,32 In the present study, we investi-
gated the in vivo role of PKCd in neutrophil migration to the
lung in a rat model of sepsis-induced indirect lung injury. In
further mechanistic studies, we investigated the in vitro role
of endothelial PKCd in regulating the crosstalk between
human neutrophils and pulmonary endothelium. Our studies
demonstrated that PKCd plays a key role in regulatingThe American Journal of Pathology - ajp.amjpathol.orgpulmonary endothelial cell adhesion molecule expression and
the inﬂux of neutrophils in response to indirect acute lung
injury. In vitro studies demonstrate that endothelial PKCd is an
important regulator of neutrophil transmigration. Furthermore,
our studies demonstrated that PKCd involvement is stimulus-
dependent, acting through regulation of endothelial reactive
oxygen species (ROS) production, NF-kB activation, and
adhesion molecule expression.
Materials and Methods
Chemicals and Reagents
Recombinant human IL-1b and mouse monoclonal antibodies
against PECAM-1 were obtained from EMD Millipore (Bill-
erica,MA). Recombinant human IL-8 was obtained fromR&D
Systems (Minneapolis,MN). EGTA, fMLP,Na-orthovanadate,
4-(2-aminoethyl)-benzenesulfonyl ﬂuoride, leupeptin, protease
inhibitor cocktail, and phosphatase inhibitor cocktail were ob-
tained fromSigma-Aldrich (St. Louis,MO).Mousemonoclonal
antieVCAM-1 and polyclonal goat antieICAM-1 (for IHC)
were obtained from BD Bioscience (San Diego, CA). Mouse
monoclonal antibody against ICAM-1 was obtained from AbD
Serotec (Raleigh, NC). The Vybrant cell adhesion assay kit and
5-(and-6)-chloromethyl-20,70-dichlorodihydroﬂuorescein
diacetate, acetyl ester (CM-H2DCFDA) were obtained from
Life Technologies (Carlsbad, CA). Polyclonal rabbit anti-
human PKCd, PKCbII, PKCa, and PKCz were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal
rabbit antieVCAM-1 (for IHC), polyclonal goat anti-MPO
heavy chain (L20 clone, for IHC), horseradish peroxidase
(HRP)econjugated donkey anti-goat, and goat anti-rabbit
secondary antibodies, and 3-amino-9-ethyl-carbazole (AEC)
substrate chromogens were also obtained from Santa Cruz
Biotechnology. Pierce subcellular protein fractionation kit,
SuperSignal ULTRA chemiluminescence substrate, dimethyl
pimelimidate (DMP), and bicinchoninic acid (BCA) reagents
were obtained from Thermo Fisher Scientiﬁc (Rockford, IL).
Diphenyleneiodonium chloride (DPI) was obtained from
Enzo Life Sciences (Farmingdale, NY). Apocynin was ob-
tained from EMD Biosciences (San Diego, CA).
PKCd Inhibitor Peptide Synthesis
PKCd activity was selectively inhibited by a peptide an-
tagonist that consisted of a peptide derived from the ﬁrst
unique region (V1) of PKCd (SFNSYELGSL; amino acids
8 to 17) coupled via an N-terminal CyseCys bond to a
membrane-permeant peptide sequence in the HIV TAT gene
product (YGRKKRRQRRR; amino acids 47 to 57 of TAT).33
Coupling this inhibitor to amembrane-permeant TAT peptide
sequence permits effective intracellular delivery into target
cells.22e24,33,34 Extensive in vitro and in vivo studies have
demonstrated that, when taken up by cells, the PKCd-TAT
peptide produces a unique dominant-negative phenotype that
effectively inhibits activation of PKCd, but not other PKC201
Mondrinos et alisotypes.22,33,34 The PKCd-TAT peptide was also synthesized
with a ﬂuorescent tag, 5,6-carboxytetramethylrhodamine
(TMR), at a noncritical site on the inhibitor portion of the
peptide complex, to monitor in vivo lung distribution. This is
critical, because the CyseCys disulﬁde bond between the
inhibitory peptide and TAT peptide is subject to cleavage via
reduction in the reducing environment of the cytoplasm. A
carrierecarrier dimer (TAT-TAT) was used as a peptide
control. The peptides were synthesized by Mimotopes (Mel-
bourne, Australia) by 9-ﬂuorenylmethoxycarbonyl solid-phase
chemistry. Peptides were puriﬁed to >95% by preparative
reverse-phase high-performance liquid chromatography.
Animal Protocol
Animal procedures and handling were conducted in accor-
dance to National Institutes of Health standards and were
approved by the Institutional Animal Care and Use Committee
at Temple University School of Medicine. Male Spraguee
Dawley rats (225 to 250 g) (Charles River Laboratories Inter-
national, Wilmington, MA) were used in all experiments. Rats
were housed in a climate-controlled facility andwere given free
access to food and water. Sepsis was induced by the cecal
ligation and puncture (CLP)method, as described previously.24
For controls, sham surgery (laparotomy without cecal ligation
or puncture) was performed. In the CLP animal groups, closure
of the abdominal incision was followed by open tracheotomy
with a 24-gauge intravenous cannula.24 Animals were ran-
domized to receive either the PKCd-TAT inhibitory peptide
(200 mg/kg in 200 mL of PBS), the TAT-TAT control peptide
(200 mg/kg in 200 mL of PBS), or a like volume of PBS
(vehicle). This dose of the PKCd inhibitor was selected based
on in vitro and in vivo studies.23,24,34 After the procedure, the
cannula was removed and the skin incision closed.
At 24 hours after surgery, animals were euthanized. The
lungs were gravity-ﬁxed with 10% neutral buffered formalin
instillation into the airways; the trachea was then tied off, to
maintain inﬂation during ﬁxation. Lungs were ﬁxed for 2 to
3 hours at room temperature, then held overnight in formalin
at 4C. After ﬁxation, lungs were washed several times with
PBS and stored in 70% ethanol (EtOH) at 4C. Lung tissue
samples were obtained from different locations (left and
right lung) and depths (ventral and dorsal), to assess the
uniformity of observed histological features and patterns of
protein localization. Lung tissue was parafﬁn-embedded, cut
into sections (8 to 10 mm thick), and stained with H&E or
with speciﬁc antibodies for immunohistochemical detection
of myeloperoxidase (MPO), ICAM-1, and VCAM-1.
Immunohistochemical Localization of MPO, ICAM-1,
and VCAM-1
Rat lung tissue sections were deparafﬁnized according to
standard protocols. Antigen retrieval was achieved by
boiling the tissue slides for 4 to 20minutes in citrate buffer pH
6.0, as needed and when applicable. In our hands, with the202speciﬁc antibodies used, ICAM-1 required only brief boiling
(4minutes),MPO required a longer period of boiling (15 to 20
minutes), and VCAM-1 did not require antigen retrieval.
After the antigen-retrieval steps, slides were blocked with 3%
bovine serum albumin (BSA). For HRP-based detection,
slides were incubated with 1.5% hydrogen peroxide for 10
minutes, to block endogenous peroxidase activity. The sec-
tions were then incubated with primary antibody (1:40 dilu-
tion for MPO, 1:200 for ICAM-1, and 1:50 for VCAM-1) for
2 to 4 hours at room temperature (ICAM-1 and MPO) or
overnight at 4C (VCAM-1). Secondary detection was per-
formed using an Alexa Fluor 488econjugated donkey anti-
goat secondary antibody (Life Technologies) for ﬂuorescence
visualization of MPO and ICAM-1 staining. For chromogen-
based visualization of ICAM-1 and VCAM-1 staining, HRP-
conjugated secondary antibodies were applied and the stains
were developed using the AEC chromogen. All secondary
antibodies were diluted 1:1000. Negative controls were pro-
cessed by omitting the primary antibody.
Representative photomicrographs were taken using a stan-
dard light and ﬂuorescence microscope and image acquisition
software SPOT version 4.5 (Diagnostic Instruments, Inc.,
Sterling Heights, MI). Cellular localization of ICAM-1 and
VCAM-1 throughout the various levels of the pulmonary
endothelium and lung parenchyma was determined based on
known morphology. ImageJ software version 1.46r (NIH,
Bethesda, MD) was used to count the total numbers of nuclei
(DAPI stain) and of MPOþ cells in ﬂuorescence micrographs,
allowing for calculation of the percentage of total cells. Auto-
mated counts were validated with manual counts in selected
micrographs. Counts were typically performed on a minimum
of10randomly acquiredﬁeldsper animal, per group,withnZ4
animals each for sham surgery, CLPþPBS, CLPþPKCd-TAT,
and CLPþTAT-TAT groups. At a minimum, 40 ﬁelds (400)
were counted per group.
Biodistribution of PKCd-TAT Inhibitory Peptide in the
Lung after IT Delivery
The uptake and distribution of the ﬂuorescently labeled
(TMR-tagged) PKCd-TAT peptide was monitored after
intratracheal (IT) delivery of the peptide (200 mg/kg). At 30
minutes after IT administration, as described above, the rats
were euthanized and lungs were gravity-ﬁxed and processed
for parafﬁn embedding, as described above. Sections (10
mm thick) were cut, mounted on slides, deparafﬁnized, and
rehydrated before DAPI counterstaining. Visualization of
TMR ﬂuorescence was performed on a standard ﬂuores-
cence microscope, and cellular uptake (with an emphasis
on the pulmonary endothelium) was assessed based on
morphology and location in the tissue.
Endothelial Cell Culture
Human pulmonarymicrovascular endothelial cells (PMVECs)
were obtained from Lonza (Walkersville, MD) and wereajp.amjpathol.org - The American Journal of Pathology
PKCd Regulates Neutrophil Migrationcultured using endothelial growth medium 2 (Lonza) with
added bovine brain extract, vascular endothelial growth factor,
epidermal growth factor, gentamicin, and hydrocortisone ac-
cording to the manufacturer’s speciﬁcations. Cells were ob-
tained at passage 5 and used between passages 5 and 8. Cells
were passed fromT-25ﬂasks to experimental plateswhen 70%
to 80% conﬂuent. PMVECs were detached using trypsine
EDTA and were cultured on collagen-coated (type IV, human
placental collagen; Sigma-Aldrich) Transwell inserts (Costar,
3.0-mm pore size; Corning Life Sciences, Tewksbury,MA) for
transmigration experiments, or on 96-well plates for cell-
surface enzyme-linked immunosorbent assays (ELISA), ROS
assays, and neutrophil adherence experiments. Medium was
changed on the cell monolayers every 48 hours.
PKCd siRNA
PMVEC monolayers were washed and incubated in EGM-2
medium without antibiotics for 24 hours. Cells were washed
and treated with Validated Stealth RNAi (Life Technologies)
to target PKCd (target sequence 50-CCACUACAUCAAG-
AACCAUGAGUUU-30), as described previously.22 siRNA
with equivalent percentage of GC nucleotide content was
used as a control. Delivery of 500 nmol/L Validated Stealth
siRNA with Invitrogen Lipofectamine 2000 transfection re-
agent (Life Technologies) was performed in OPTI-MEM I
reduced-serum medium (Life Technologies). After 4 to 6
hours of transfection, the cells were cultured in EGM-2 with
antibiotics for 48 hours. PKCd knockdown efﬁciency and
speciﬁcity were monitored by immunoblotting for PKCd and
other PKC isotypes (PKCa, PKCbII, and PKCz).
Preparation of Human Neutrophils
Neutrophils were isolated from 10 U/mL heparinized venous
blood obtained from healthy adult donors, after informed
consent, in accordance with Institutional Review Board pro-
tocols at Temple University (Philadelphia, PA). Donors were
healthy adult (over the age of 18) men and women who were
recruited from the Temple University community. Standard
isolation techniques35 were used with FicolleHypaque (GE
Healthcare, Pittsburgh, PA) centrifugation, followed by
dextran sedimentation and hypotonic lysis to remove residual
erythrocytes. Cells were suspended in 10 mmol/L HEPES
buffer (pH 7.4). Neutrophil viability was 98%, as determined
by Trypan Blue exclusion.
Neutrophil Transendothelial Migration
PMVECs were seeded on collagen-coated Transwell inserts
(24-well plates) and were cultured until the monolayers
were conﬂuent. PMVEC monolayer conﬂuency was moni-
tored by measuring resistance changes across the endothelial
cell monolayer using an EndOhm epithelial voltohmmeter
(World Precision Instruments, Sarasota, FL).36 The micro-
vascular endothelial cell monolayers reached an averageThe American Journal of Pathology - ajp.amjpathol.orgresistance of 18 to 20 U/cm2 across the monolayer within 5
to 6 days. The cells were pretreated with buffer or 2 mmol/L
PKCd inhibitor before the addition of 10 U/mL IL-1b.
Neutrophils (1  106 cells per well) were added to the upper
wells and allowed to migrate across the PMVECs for 90
minutes at 37C in a 5% CO2eenriched atmosphere. In
siRNA experiments, cells were treated with PKCd targeted
siRNA or percent-GC control RNA (as described above).
After PKCd depletion, cells were treated with 10 U/mL IL-
1b. Neutrophils (1  106 per well) were added to the upper
wells and allowed to migrate across PMVECs for 90 mi-
nutes at 37C in a 5% CO2eenriched atmosphere. After
incubation, the Transwell inserts were removed, and neu-
trophils in the bottom wells were counted. In some experi-
ments, just before the addition of neutrophils to the top well,
2 nmol/L IL-8 or 1 nmol/L fMLP was added to the bottom
well of PMVEC monolayers pretreated with buffer only or
with 2 mmol/L PKCd inhibitor. After 90 minutes at 37C in
a 5% CO2eenriched atmosphere, the Transwell inserts were
removed and the migrated neutrophils were counted.
Neutrophil Binding to PMVECs
PMVEC monolayers were grown to conﬂuency on 96-well
plates and pretreated with buffer, 10 U/mL IL-1b, or 0.01 to
10 mmol/L IL-1bþPKCd inhibitor for 18 hours. Isolated
neutrophils were suspended in Dulbecco’s modiﬁed Ea-
gle’s mediumþBSA (0.2%) at a concentration of 2  106
cells/mL and incubated with the acetoxymethyl ester of
calcein for 30 minutes at 37C, according to the manu-
facturer’s instructions (Vybrant cell adhesion assay kit;
Life Technologies). The cells were washed, and 2.5  105
calcein-loaded neutrophils per well were added to PMVEC
monolayers and incubated for 30 minutes at 37C. Non-
adherent neutrophils were removed by careful washing.
Neutrophil binding was determined ﬂuorometrically using
a FlexStation ﬂuorescence microplate reader (Molecular
Devices, Sunnyvale, CA) at an excitation wavelength of
494 nm and an emission wavelength of 515 nm. The
number of bound neutrophils was calculated from a stan-
dard curve prepared from calcein-loaded neutrophils.
Surface Expression of ICAM-1, VCAM-1, and PECAM-1
on PMVECs
The surface expression of ICAM-1, VCAM-1, and
PECAM-1 on PMVECs was determined by a cell-surface
ELISA.37 PMVECs were grown to conﬂuence on 96-well
plates and then were pretreated with buffer or 0.01 to 5
mmol/L PKCd inhibitor for 1 hour before the addition of 10U/
mL IL-1b. In some experiments, the cells were pretreated
with 10 mmol/L ROS inhibitors DPI and 500 mmol/L apoc-
ynin or their respective controls [ie, dimethyl sulfoxide
(DMSO) or EtOH] before the addition of IL-1b. The cells
were incubated for 18 hours, washed twice in washing buf-
fer (PBS with 0.5% BSA, 1 mmol/L CaCl2, and 1 mmol/L203
Mondrinos et alMgCl2), and then ﬁxed for 15 minutes at room temperature in
1% paraformaldehyde. The cell monolayers were washed and
blocked for 1 hour at 37C in blocking buffer (washing buffer
with 2% BSA). The cells were incubated with 0.05 mg/mL
anti-human ICAM-1 (clone 6.5B5; AbD Serotec), 0.25 mg/
mL VCAM-1 (clone 51-10C9; BD Pharmingen, San Diego,
CA), or 0.25 mg/mL PECAM-1 (clone P2B1; EMD Milli-
pore) for 1 hour, washed, and incubated with goat anti-mouse
IgG conjugated to HRP (1:1000) for 1 hour. The cell mono-
layers were washed, tetramethylbenzidine liquid substrate
(Sigma-Aldrich) was added, and optical density at 650 nm
(OD650) was determined. Mouse IgG1 was used as an isotype
control at a concentration of 0.25 mg/mL for VCAM-1 and
PECAM-1 ELISA and 0.05 mg/mL for ICAM-1 ELISA. The
value obtained with mouse IgG1 was subtracted from the
value obtained for expression of each adhesion molecule.
Preparation of PMVEC Nuclear Fractions
PMVEC monolayers were incubated with buffer or 10 U/
mL IL-1b in the absence or presence of 2 mmol/L of the
PKCd inhibitor or 10 mmol/L of the ROS inhibitor DPI for
15 minutes. Nuclear extracts were prepared using a Pierce
subcellular protein fractionation kit (Thermo Fisher Scien-
tiﬁc) according to the manufacturer’s instructions. Samples
for Western blot analysis were prepared by mixing an
aliquot of the nuclear extracts with 2 sample buffer and
heating for 15 minutes at 65C. Purity of nuclear fractions
was routinely determined by probing fractions for cyto-
plasmic (lactate dehydrogenase) and nuclear (HDAC-2)
markers. Nuclear extracts were run on a 4% to 12% gradient
SDS-PAGE, transferred to a nitrocellulose membrane, and
blocked for 1 hour at room temperature with Tris-buffered
saline (pH 7.5) containing 0.1% Tween 20 and 1% BSAe
3% casein.20 The membranes were incubated with a rabbit
polyclonal anti-p65 NF-kB antibody, washed, and incubated
with HRP-conjugated goat anti-rabbit IgG. Immunoreactive
bands were visualized using Pierce SuperSignal ULTRA
chemiluminescence substrate (Thermo Fisher Scientiﬁc).
Translocation of the p65 NF-kB subunit to the nucleus was
quantitated by densitometry analysis of Western blots with
ImageJ software version 1.46r (NIH) and the values were
expressed in arbitrary densitometry units.
PMVEC ROS Production
PMVEC monolayers were incubated with 10 mmol/L cell
permeable ﬂuorogenic probe 5-(and-6)-chloromethyl-20,70-
dichlorodihydroﬂuorescein diacetate, acetyl ester (CM-
H2DCFDA; Life Technologies) for 1 hour at 37C in a 5%
CO2eenriched atmosphere. Cells were washed and then
incubated  2 mmol/L PKCd inhibitor for 1 hour. A back-
ground reading was obtained using a FlexStation microplate
reader (Molecular Devices). IL-1b (10 U/mL) was added,
and ROS production was monitored for 2 hours. PMVECs
treated with buffer (Dulbecco’s modiﬁed Eagle’s medium204without Phenol Red) were used to correct for background
ﬂuorescence, and 100 mmol/L H2O2 was used as a contin-
uous oxidant to conﬁrm loading of the probe.
ROS Inhibitor Assays
VCAM-1 expression and p65 NF-kB nuclear translocation
were assayed in the presence or absence of the ROS in-
hibitors DPI in DMSO or apocynin in EtOH. In brief,
PMVECs were cultured to conﬂuence and pretreated with
10 mmol/L DPI or 500 mmol/L apocynin for 15 minutes at
37C in a 5% CO2eenriched atmosphere. In VCAM-1
expression assays, cells were treated with 10 U/mL IL-1b
for 18 hours and expression was determined by cell-surface
ELISA, as described above. In NF-kB translocation assays,
PMVECs were pretreated with 10 mmol/L DPI for 15 mi-
nutes and then were stimulated with 10 U/mL IL-1b for
15 minutes at 37C in a 5% CO2eenriched atmosphere.
Nuclear fractions were prepared and the presence of nuclear
p65 NF-kB was determined by immunoblotting, as described
above.
Statistical Analysis
Data were analyzed by Student’s t-test for two group
comparisons or analysis of variance followed for multiple
comparisons. The TukeyeKramer multiple comparisons
post-test was used to evaluate the signiﬁcance between
experimental groups if analysis of variance indicated a
signiﬁcant difference. Differences were considered signiﬁ-
cant if P < 0.05. Data are expressed as means  SEM for
the number (n) of studies performed.
Results
Biodistribution of the PKCd Inhibitor in the Lung
Previously, our research group demonstrated that IT ad-
ministration of a TAT-conjugated, highly speciﬁc PKCd
peptide inhibitor decreases inﬂammation and exerts a lung-
protective effect in a rat model of sepsis-induced lung
injury.24 Coupling of the PKCd inhibitory peptide to a
protein transduction domain (TAT peptide) permits effec-
tive intracellular delivery into multiple cell types22,23,33,34
and transport across highly impermeable barriers in vivo.38
However, the biodistribution of this peptide within the
lung after IT administration had not previously been
examined. The endothelium is a key target, given that pul-
monary endothelial cells have an active role in the recruit-
ment of neutrophils and are important contributors to the
pathogenesis of acute lung injury or ARDS.39 We therefore
determined the distribution and uptake of the ﬂuorescent
TMR-tagged inhibitor within the lung, to ascertain whether
the inhibitor penetrates the pulmonary epithelium and is
taken up by lung parenchyma cells after IT delivery of the
peptide. Qualitative assessment of TMR ﬂuorescence inajp.amjpathol.org - The American Journal of Pathology
Figure 1 TAT-mediated transport facilitates uptake of the PKCd
inhibitory peptide throughout the pulmonary endothelium and peripheral
lung parenchyma. Rat lungs were gravity-ﬁxed 30 minutes after IT
administration of a ﬂuorescent TMR-tagged TAT-conjugated PKCd inhibitory
peptide. Representative lung tissue sections are shown (nZ 3 animals). A:
TMR ﬂuorescence (red) reveals largely homogeneous distribution of the
peptide throughout the peripheral lung parenchyma, in the endothelium of
small veins and arterioles (arrows), and in alveolar wall cells (inset). B:
Robust TMR ﬂuorescence (red) indicates uptake of the peptide in large
vessel endothelium (arrows) and surrounding parenchyma. C: Cropped view
of TMR ﬂuorescence (red) in the capillary of an alveolar septum (arrows),
indicating uptake of the peptide at the level of capillary endothelium.
Original magniﬁcation: 100 (A and B); 400 (C).
Figure 2 Lung protective effects of IT administration of PKCd-TAT in
the setting of sepsis-induced indirect lung injury are speciﬁc to the PKCd
inhibitory peptide sequence. H&E staining in representative lung tissue
sections from 24 hours after surgery (n Z 4 animals per group). A: In the
sham-surgery group, lung architecture was normal, with open alveoli and
thin alveolar walls. B: In the CLPþPBS group, by 24 hours sepsis had
induced indirect pulmonary injury, with widespread inﬂammatory inﬁltrate,
thickening of alveolar walls and septa, as well as visible hemorrhaging and
proteinaceous exudate ﬁlling some alveoli. C: In the CLPþTAT-TAT group,
histopathological features were similar to those of the CLPþPBS group,
indicating that the TAT peptide sequence does not exert a lung-protective
effect. D: PKCd inhibition limited the development of histological changes
consistent with lung injury, with reduced inﬂammatory inﬁltrate, mainte-
nance of alveolar wall thickness, and an absence of hemorrhaging and
proteinaceous exudate induced by sepsis. Scale bars: 100 mm (left
column); 50 mm (right column). Original magniﬁcation: 100 (left
column); 400 (right column).
PKCd Regulates Neutrophil Migrationlung tissue sections revealed consistent, largely homoge-
neous distribution throughout the distal lung parenchyma
(Figure 1A). The inhibitory peptide was observed in alve-
olar wall cells, as well as in the endothelial cells lining small
veins and arterioles (Figure 1A). Robust TMR ﬂuorescence
was also consistently observed at all levels of the pulmonary
endothelium, from the large pulmonary vessels (Figure 1B)
down to the capillary endothelium of the alveoli (Figure 1,
A and C). Thus, IT administration of the PKCd-TAT pep-
tide results in penetration of the epithelium and uptake of
the inhibitor by pulmonary endothelial cells and throughout
the lung parenchyma, indicating that direct effects of PKCd
inhibition in endothelial cells are likely widespread and may
contribute to the observed therapeutic effects in the lung on
septic challenge.
IT Administration of a PKCd-TAT Inhibitory Peptide
Attenuates Sepsis-Induced Lung Injury and Neutrophil
Inﬂux 24 Hours after CLP
To conﬁrm that the protection observed in our model of
indirect pulmonary injury is mediated through speciﬁc ef-
fects of the PKCd inhibitory peptide (SFNSYELGSL),
rather than nonspeciﬁc effects of the TAT protein trans-
duction domain peptide (YGRKKRRQRRR), we compared
the effects of IT administration of the PKCd-TAT peptide
and the TAT-TAT control peptide after CLP. Lung sections
were prepared 24 hours after sham or CLP surgery and were
evaluated for alterations consistent with lung injury. In the
sham-surgery rats, H&E staining demonstrated normal lung
architecture, with occasional small foci of inﬂammatory
inﬁltrates, but no appreciable thickening of alveolar walls
and septa (Figure 2A). Lungs from CLPþPBS rats exhibited
histopathological features consistent with acute inﬂamma-
tion and indirect pulmonary injury, including increased in-
ﬂammatory cell inﬁltrate, thickening of alveolar walls and
septa, and an overall disruption of alveolar architectureThe American Journal of Pathology - ajp.amjpathol.org(Figure 2B), all of which are hallmark histopathological
features of clinical ARDS.4,40 Lungs from CLPþTAT-TAT
rats had all of the same histopathological features seen in the
lungs of CLPþPBS rats (Figure 2C), indicating an absence
of therapeutic effects mediated by the TAT peptide sequence.
By contrast, the lungs of CLPþPKCd-TAT rats had a his-
tological appearance similar to that of sham-surgery controls
(Figure 2D), indicating a speciﬁc therapeutic effect of the
PKCd inhibitory peptide. PKCd inhibition preserved nor-
mal lung architecture, with marked reductions in the
CLP-induced inﬂammatory inﬁltrates, without the alveolar
wall thickening, hemorrhaging, and proteinaceous exudate
induced by sepsis.
Intra-abdominal sepsis produces systemic inﬂammation
and inﬂux of neutrophils into the lung, a hallmark of clinical
ARDS.2,5e7,41 To assess the degree to which the observed
decreases in cellular inﬁltrates on PKCd inhibition reﬂect205
Figure 3 IT administration of PKCd-TAT attenuates neutrophil migra-
tion into rat lung and attenuates ICAM-1 expression in sepsis-induced
indirect lung injury. Immunohistochemical detection of MPO in represen-
tative lung tissue sections from 24 hours after surgery (nZ 4 animals per
group). In the sham surgery group, only a few MPOþ cells were seen in each
ﬁeld. In the CLPþPBS group, sepsis induced inﬁltration of numerous MPOþ
cells throughout the lung parenchyma. Administration of the TAT-TAT
control peptide had no signiﬁcant effect on sepsis-induced inﬂux of
MPOþ cells into the parenchyma, compared with CLPþPBS vehicle.
Administration of the inhibitory peptide led to a signiﬁcant reduction of
sepsis-induced MPOþ cell numbers in the lung. After primary antibody in-
cubation, ICAM-1 was visualized using an Alexa Fluor 488econjugated
secondary antibody (green), with DAPI counterstaining (blue). Represen-
tative lung tissue sections from 24 hours after surgery are shown (n Z 4
animals per group). In the sham surgery group, levels of ICAM-1 were barely
detectable. In the CLPþPBS group, widespread and intense sepsis-induced
ICAM-1 staining throughout the lung parenchyma was observed. In the
CLPþTAT-TAT group, high levels of ICAM-1 were observed, with distribution
similar to that of the CLPþPBS group. In the CLPþPKCd-TAT group, marked
reduction in sepsis-induced ICAM-1 expression was observed, with some
small patches of staining seen in alveoli. Scale bars: 50 mm (left column);
100 mm (right column).
Mondrinos et aldecreased neutrophil inﬂux, we performed immunohisto-
chemistry to detect MPOþ cells in lung tissue sections
(Figure 3). The lungs of sham-surgery rats had very low
numbers of MPOþ cells (2.2  1.2% of total cells)
(Figure 3). By contrast, the lungs of CLPþPBS rats had
signiﬁcantly higher numbers of MPOþ cells (23.4  6.8%
of total cells; P < 0.001 versus sham surgery), indicative of
acute lung inﬂammation (Figure 3). The lungs of
CLPþTAT-TAT rats had similarly elevated levels of MPOþ
cells (21.6  7.8% of total cells; P < 0.001 versus sham
surgery) (Figure 3). Consistent with the decreased cellular
inﬁltrate observed with H&E staining, IT delivery of the
PKCd-TAT peptide signiﬁcantly reduced the number of
MPOþ cells in the lungs of CLP septic rats to near the level
of sham-surgery controls (7.4  3.1% of total cells; P <
0.001 versus CLPþPBS vehicle) (Figure 3).
Inhibition of PKCd Reduces ICAM-1 and VCAM-1
Expression in Lung Tissue after Septic Challenge
ICAM-1 and VCAM-1 are key adhesion molecules involved
in neutrophil recruitment to the lung in sepsis, and are
known to be up-regulated on activation of vascular endo-
thelium by proinﬂammatory cytokines released during
sepsis.6,42 To test the hypothesis that PKCd promotes
increased expression of ICAM-1 and VCAM-1 in sepsis-
induced lung injury, and that decreased expression of
these adhesion molecules is in part responsible for the lung-
protective effect of PKCd inhibition through decreased
neutrophil inﬂux,24 we compared expression of ICAM-1
and VCAM-1 in the lungs across experimental groups.
To examine ICAM-1 expression in septic lung tissue, we
performed immunohistochemistry with ﬂuorescence visu-
alization to assess overall levels and distribution of ICAM-1
(Figure 3), as well as AEC chromogenebased detection to
visualize ICAM-1 in the context of the overall histological
appearance of the tissue and to identify cellular localization
(Figure 4). At 24 hours after surgery, there was only scant
ICAM-1 expression in the alveolar walls of lungs from sham-
surgery rats, whereas the lungs of both CLPþPBS and
CLPþTAT-TAT rats exhibited widespread ICAM-1 locali-
zation throughout the parenchyma and alveolar walls
(Figure 3). ICAM-1 localization in the lungs of CLPþPKCd-
TAT rats was not nearly as widespread or robust as seen in
the other two CLP groups, but was appreciably higher than in
sham-surgery controls (Figure 3).
AEC chromogen-based visualization of ICAM-1 in the
lungs of CLPþPBS rats revealed widespread and robust
ICAM-1 expression throughout the pulmonary endothelium,
including the pulmonary arteries and veins as well as the
alveolar microcirculation throughout the parenchyma
(Figure 4A). In addition, the disruption of lung architecture,
interstitial thickening, and increased cellularity that are
hallmarks of sepsis-induced lung injury were clearly evident
in the CLP septic animals. By contrast, sham-surgery con-
trols had normal lung architecture and cellularity, with206barely detectable ICAM-1 stain in the alveolar microcircu-
lation (Figure 4A). There was a signiﬁcant reduction in the
distribution and intensity of ICAM-1 staining in the lungs of
CLPþPKCd-TAT rats, and this was associated with pres-
ervation of a more histiotypic lung architecture (Figure 4A).
In the CLPþPKCd-TAT rats, some ICAM-1 staining was
still evident in capillaries of the alveolar walls, compared
with sham-surgery controls (Figure 4A). However, the
capillary ICAM-1 staining in the lungs of CLPþPKCd-TAT
rats was less pronounced than in the CLPþPBS rats
(Figure 4A).ajp.amjpathol.org - The American Journal of Pathology
Figure 4 IT administration of the PKCd inhibitor attenuates sepsis-
induced expression of the adhesion molecules ICAM-1 and VCAM-1 in the
pulmonary endothelium. A: Immunohistochemical detection of ICAM-1 in
representative lung tissue sections from 24 hours after surgery (minimum
of n Z 3 animals per group). After primary antibody incubation, ICAM-1
was visualized using HRP-conjugated secondary antibodies and the
peroxidase substrate chromogen AEC, which produces a red reaction
product. In the sham-surgery group, ICAM-1 staining was barely detectable,
and lung architecture was normal. In the CLPþPBS group, robust ICAM-1
localization was observed throughout the distal lung tissue and in the
large arteries accompanying the bronchial airways. In the CLPþPKCd-TAT
group, ICAM-1 staining was reduced to near the levels with sham surgery.
B: Immunohistochemical detection of VCAM-1 in representative lung tissue
sections from 24 hours after surgery (minimum of n Z 3 animals per
group). After primary antibody incubation, VCAM-1 was visualized using
HRP-conjugated secondary antibodies and the peroxidase substrate chro-
mogen AEC (red), which produces a red reaction product. B, top row: VCAM-1
staining was not detectable in the sham surgery group. A representative
VCAM-1epositive small artery situated within the injured, inﬂamed pa-
renchyma is shown for the CLPþPBS group; adhered leukocytes along the
VCAM-1þ endothelium are shown at higher magniﬁcation in the inset. In
the CLPþPKCd-TAT image, VCAM-1 staining is absent in the endothelium of
a similarly situated small artery in the distal parenchyma. B, bottom:
Cropped views of venous and arterial localization of VCAM-1. Left to right:
VCAM-1 staining in the venous endothelium (CLPþPBS); absence of VCAM-1
staining in the venous endothelium (CLPþPKCd-TAT); a large pulmonary
artery with VCAM-1þ endothelium and thickened underlying interstitium
(CLPþPBS); and a large pulmonary artery with absent VCAM-1 staining in
the endothelium, and with normal thickness of the underlying interstitium
(CLPþPKCd-TAT). Scale bars: 100 mm (A, top); 50 mm (A, bottom, and B,
top). Original magniﬁcation, 400 (B, bottom row). PA, pulmonary artery;
PV, pulmonary vein.
PKCd Regulates Neutrophil MigrationImmunohistochemical detection of VCAM-1 demon-
strated a similar pattern of staining, consistent with inﬂam-
matory activation. VCAM-1 staining was virtually absent in
the lungs of sham-surgery controls, but was consistently
observed in the pulmonary endothelium of CLPþPBS rats
(Figure 4B). Increased leukocyte adherence to the VCAM-1þThe American Journal of Pathology - ajp.amjpathol.orgendothelium was a common feature in septic lungs, and the
interstitial regions surrounding VCAM-1þ endothelium
appeared thickened and edematous, with evidence of in-
ﬂammatory inﬁltrate, all of which are hallmarks of lung
injury (Figure 4B). As was observed with ICAM-1, VCAM-1
staining in the lungs of CLPþPKCd-TAT rats was reduced to
levels similar to those of sham-surgery controls (Figure 4B).
In large pulmonary veins, the endothelium consistently
stained positive for VCAM-1 in CLPþPBS rats; this com-
ponent of the inﬂammatory response was signiﬁcantly at-
tenuated on PKCd inhibition (Figure 4B). Similarly, VCAM-1
activation in the large pulmonary arteries and the concomitant
thickening of the underlying interstitium were attenuated
on PKCd inhibition (Figure 4B), further establishing the
endothelial-speciﬁc anti-inﬂammatory and lung-protective
effects of PKCd inhibition in the setting of experimental
sepsis.
Role of PKCd in Neutrophil Transmigration
Our in vivo studies demonstrated that IT administration of the
PKCd-TAT peptide inhibitor attenuates neutrophil inﬂux and
modulates endothelial adhesion molecule expression in a
model of indirect pulmonary injury. Having conﬁrmed that
the PKCd inhibitory peptide is taken up throughout the pul-
monary endothelium in vivo (Figure 1), where it may act
directly to reduce adhesion molecule expression (Figures 3
and 4), we used an in vitro model of neutrophil trans-
migration across primary human PMVECs grown in a
Transwell culture system to delineate the role of endothelial
PKCd activity in regulating neutrophil transmigration.
Endothelial PKCd activity was inhibited using genetic
(PKCd siRNA) and pharmacological (PKCd antagonist)
techniques. Treatment of PMVECs with siRNA-depleted
PMVEC monolayers of PKCd, but not PKCa, PKCbI/II, or
PKCz (Figure 5A). There was minimal neutrophil migration
across PMVEC monolayers in the absence of stimulus (ie, in
buffer-treated PMVECs) (Figure 5B). IL-1b-mediated acti-
vation of PMVECs increased neutrophil transmigration by
more than eightfold. Neutrophil migration across IL-1be
activated endothelium was signiﬁcantly attenuated in
PMVECs depleted of PKCd. In contrast, PMVECs trans-
fected with the percent-GC control siRNA showed no
signiﬁcant differences in neutrophil migration across
IL-1betreated PMVECs, compared with PMVECs treated
with IL-1b alone. Pretreatment with PKCd-TAT also
signiﬁcantly decreased neutrophil migration across IL-
1beactivated PMVECs, compared with PMVECs treated
with IL-1bþTAT-TAT control peptide or IL-1bþvehicle,
indicating that endothelial PKCd activity is an important
component of IL-1beinduced neutrophil transmigration
(Figure 5B). Because we obtained similar results with either
the peptide antagonist or PKCd siRNA, further mechanistic
studies were performed using PKCd-TAT.
To determine whether the role of PKCd as a regulator of
neutrophil transmigration across PMVEC monolayers is207
Figure 5 Role of PKCd in neutrophil transmigration. A: Selective
depletion of PKCd by stealth PKCd siRNA in PMVECs. Controls were PMVECs
treated with siRNA with equivalent percentage of GC nucleotide content (GC
control) as the stealth PKCd siRNA. Levels of speciﬁc PKC isotypes were
determined in cell lysates by immunoblotting with isotype-speciﬁc anti-
bodies to PKCd, PKCa, PKCbI/II, and PKCz. Blots are representative of three
separate Western blotting experiments. B: Neutrophil transmigration
through IL-1beactivated PMVECs. PMVECs were grown on Transwell inserts
and incubated with IL-1b or buffer after transfection with PKCd stealth
siRNA or siRNA containing equivalent percentage of GC nucleotide content
(Control). In a second series of experiments, PMVECs were grown on
Transwell inserts and were pretreated with buffer, 10 U/mL IL-1bþvehicle,
IL-1bþTAT-TAT control peptide, or IL-1bþPKCd inhibitor. Neutrophils
(1  106 per well) were added to the upper well of the Transwell culture
system and allowed to migrate for 1.5 hours through PMVECs. C: Role of
PKCd in neutrophil transmigration mediated by IL-8 and fMLP. Chemo-
attractants fMLP (1 nmol/L) or IL-8 (2 nmol/L) were added to the bottom
well of a Transwell culture system. Neutrophils (2 106 per well) were added
to the upper well and were allowed to migrate for 1.5 hours through PMVECs
pretreated with buffer or with 2 mmol/L PKCd inhibitor. Data are expressed as
means  SEM. nZ 4 (B, siRNA experiments); nZ 3e9 (B, PKCd inhibitor
experiments); n Z 6e9 (C). **P < 0.01, ***P < 0.001 versus respective
control or controls (B). **P < 0.01 fMLP versus fMLPþPKCd inhibitore
treated PMVECs; ***P < 0.001 fMLP or IL-8 versus buffer (C).
Figure 6 Neutrophil binding to IL-1beactivated PMVECs is PKCd
dependent. PMVEC monolayers were treated overnight with buffer or 10 U/
mL IL-1b  0.5 to 10 mmol/L PKCd inhibitor. Calcein-loaded neutrophils (2
 105) were incubated with PMVECs for 30 minutes at 37C. Neutrophil
binding was calculated from a standard curve prepared from calcein-loaded
neutrophils. Data are expressed as means  SEM from one representative
experiment, performed in triplicate, from four different neutrophil donors.
**P < 0.01 IL-1b versus IL-1bþPKCd inhibitor (1 to 10 mmol/L); ***P <
0.001 buffer versus IL-1b.
Mondrinos et alstimulus dependent, we used fMLP and IL-8, two diverse
signaling molecules known to elicit different modes of
neutrophil recruitment. In these experiments, the chemo-
attractants were added to the lower chamber of the Trans-
well culture system just before the addition of neutrophils to
the upper well. Both fMLP and IL-8 triggered signiﬁcant
neutrophil transmigration through PMVECs, compared with208buffer alone (Figure 5C). Pretreatment of the PMVEC
monolayers with the PKCd inhibitor signiﬁcantly attenuated
neutrophil migration in response to fMLP. By contrast,
inhibition of PKCd activity had no signiﬁcant effect on
IL-8emediated neutrophil transmigration, indicating a
PKCd-independent mechanism. Thus, PKCd activation is
required for migration through IL-1beactivated endothe-
lium or in response to the chemotactic peptide fMLP, but
PKCd activity is not required for IL-8emediated migration.
Role of PKCd in Neutrophil Binding and Adhesion
Molecule Expression in PMVECs
To further identify the regulatory role of PKCd in neutrophil
transmigration, we investigated whether PKCd activity has a
functional role in neutrophileendothelial cell interaction and
expression of adhesion molecules required for migration. The
effect of endothelial PKCd inhibition on IL-1bemediated
neutrophil adherence was determined using PMVEC mono-
layers. Treatment of PMVECs with IL-1b signiﬁcantly
enhanced calcein-labeled neutrophil adherence to PMVEC
monolayers, compared with unstimulated PMVEC mono-
layers (Figure 6). Incubation with the PKCd inhibitor
decreased neutrophil adherence to IL-1bestimulated PMVEC
monolayers in a dose-dependent manner. In contrast, PKCd
inhibition had no effect on neutrophil adhesion to nonactivated
PMVECs, suggesting that PKCd involvement is limited to
proinﬂammatory signaling pathways.ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Role of PKCd in PMVEC adhesion molecule expression. The expression of VCAM-1, ICAM-1, and PECAM-1 on PMVEC monolayers was determined by
a cell-surface ELISA. Human PMVEC monolayers were treated overnight with buffer or IL-1b  PKCd inhibitor (0.01 to 5 mol/L). A: IL-1bestimulated VCAM-1
expression. Constitutive expression of VCAM-1 (buffer) was normalized to 1, and expression in response to IL-1b treatment  PKCd inhibitor was compared
with constitutive VCAM-1 expression. B: IL-1bestimulated ICAM-1 expression, relative to constitutive ICAM-1 expression (as described for A). C: IL-
1bestimulated PECAM-1 expression, relative to constitutive PECAM-1 expression (as described for A). Data are expressed as means  SEM. nZ 7 (A); nZ 5
(B); n Z 6 (C). **P < 0.01, buffer versus IL-1betreated PMVECs, yP < 0.01, IL-1betreated PMVECs versus 10 U/mL IL-1bþPKCd inhibitor (0.1e5 mmol/L)
(A). *P < 0.05, IL-1betreated PMVECs versus IL-1bþPKCd inhibitor (0.1 mmol/L); **P < 0.01, IL-1betreated PMVECs versus IL-1bþPKCd inhibitor (1e5
mmol/L); and ***P < 0.001, buffer versus IL-1betreated PMVECs (B).
PKCd Regulates Neutrophil MigrationEndothelial adhesionmolecules such as ICAM-1, VCAM-1,
and PECAM-1 have been identiﬁed as important regulators
of neutrophil adhesion and transmigration through pulmo-
nary endothelium in response to IL-1b and fMLP, but not
IL-8.2,43e45We next investigated whether PKCd has a role in
regulating IL-1bemediated PMVEC activation. PMVEC
monolayers were activated with IL-1b in the absence or
presence of the PKCd inhibitor. There was little VCAM-1 or
ICAM-1 expression on PMVEC monolayers under basal or
resting conditions (Figure 7, A and B). IL-1b stimulated a
signiﬁcant increase in expression of both VCAM-1 and
ICAM-1. IL-1bemediated expression of VCAM-1 and
ICAM-1 was signiﬁcantly attenuated in a dose-dependent
manner by incubation with the PKCd inhibitor, indicating
a regulatory role for PKCd in cytokine-mediated activation
of PMVECs. In contrast, PECAM-1 expression was inde-
pendent of both IL-1b treatment and PKCd inhibition
(Figure 7C). Thus, PKCd selectively regulates activation of
PMVECs and IL-1beinduced cell-surface expression of
ICAM-1 and VCAM-1 but not PECAM-1. Furthermore, the
decreased expression of ICAM-1 and VCAM-1 after inhi-
bition of PKCd was associated with decreased adherence of
neutrophils to activated endothelium.PKCd Regulates IL-1beMediated Activation of NF-kB
IL-1bemediated VCAM-1 and ICAM-1 expression is
dependent on activation of the transcription factor NF-kB,46
and we have previously demonstrated a role for PKCd in
NF-kB activation in TNF-treated human neutrophils.20,21 In
addition, PKCd is implicated as an important regulator
of NF-kB in other types of endothelial or epithelial
cells.26,30,31,47e50 To investigate the role of PKCd in IL-1be
mediated activation of NF-kB in PMVECs, we determined
the effect of PKCd inhibition on p65 NF-kB translocationThe American Journal of Pathology - ajp.amjpathol.orgto the nucleus. In the absence of stimuli, there was little
detectable p65 NF-kB present in the nuclear fraction of
PMVECs (Figure 8A). The addition of IL-1b to PMVEC
monolayers resulted in a fourfold increase in NF-kB trans-
location, which was signiﬁcantly attenuated by PKCd inhibi-
tion, indicating a role for PKCd in regulating IL-1bemediated
activation of NF-kB in PMVECs.
A Regulatory Role for ROS in IL-1beMediated NF-kB
Activation and Adhesion Molecule Expression
ROS produced by endothelial cells in response to cytokines
are important regulators of the inﬂammatory response, and
endothelial-derived redox signaling is implicated in regu-
lating neutrophil transmigration.51,52 Of speciﬁc importance
to our experimental system, IL-1b activates ROS production
via NADPH oxidase (Nox2).53 To determine the role of ROS
production in IL-1bestimulated NF-kB activation and
adhesion molecule expression, we pretreated PMVEC
monolayers with the ROS inhibitors DPI and apocynin
before adding IL-1b. ROS inhibition signiﬁcantly decreased
IL-1beinduced expression of VCAM-1, compared with
IL-1b treatment alone or with the appropriate vehicle
(Figure 8B). ROS inhibition also decreased IL-1bemediated
nuclear translocation of p65 NF-kB (P < 0.04, IL-1þvehicle
versus IL-1þDPI) (n Z 3), indicating a role for ROS pro-
duction in NF-kB activation and adhesion molecule expres-
sion in response to IL-1b treatment of PMVECs.
PKCd Inhibition Attenuates ROS Production in
IL-1beTreated PMVECs
ROS production requires assembly of the NOX complex,
and different PKC isotypes (including PKCd) have been
implicated in the assembly and activation of these enzyme209
Figure 8 Role for PKCd in IL-1bemediated ROS production and
activation of the redox-sensitive transcription factor NF-kB. A: IL-
1bemediated p65 NF-kB translocation is PKCd dependent. PMVECs were
treated with buffer or 10 U/mL IL-1b  PKCd inhibitor. Nuclear ex-
tracts, prepared after 15 minutes of incubation, were probed for the
presence of p65 NF-kB by Western blotting. Representative blots are
shown, with quantitation. HDAC-2 is a marker for nuclear fractions. B:
Regulatory role for ROS in IL-1bemediated VCAM-1 expression in
PMVECs. VCAM-1 expression was measured by cell-surface ELISA.
Constitutive expression of VCAM-1 (buffer) was normalized to 1, and
expression in response to IL-1b treatment  the ROS inhibitors DPI (10
mmol/L) or apocynin (APO; 500 mmol/L) or appropriate vehicle controls
(DMSO and EtOH, respectively) was compared. C: PKCd inhibition at-
tenuates ROS production in IL-1betreated PMVECs. CM-H2DCFDAeloa-
ded PMVEC monolayers were treated with 10 U/mL IL-1b  2 mmol/L
PKCd inhibitor. Controls (Dulbecco’s modiﬁed Eagle’s medium) exhibited
no change in oxidation of the probe, and H2O2 conﬁrmed presence of
the probe (data not shown). Graph in C is representative of four
separate experiments run in triplicate (P < 0.03 IL-1b versus IL-
1bþPKCd inhibitor). Data are expressed as means  SEM (A and B).
n Z 5 (A); n Z 4 (B). ***P < 0.001 IL-1betreated PMVECs versus
buffer-treated PMVECs; yP < 0.001 IL-1betreated PMVECs versus IL-
1bþPKCd inhibitoretreated PMVECs (A). ***P < 0.001 buffer versus IL-
1b, IL-1bþDMSO, and IL-1bþEtOH; yP < 0.001 IL-1bþDPI versus IL-1b
and IL-1bþDMSO; and **P < 0.001 IL-1bþAPO versus IL-1b and IL-
1bþEtOH (B).
Mondrinos et alcomplexes.23,54,55 To investigate whether PKCd regulates
IL-1bemediated NOX activation in PMVECs, we exam-
ined the effect of PKCd inhibition on ROS production. In
PMVECs, IL-1b elicited a rapid and sustained production of
ROS in PMVEC monolayers (Figure 8C). PKCd inhibition
signiﬁcantly attenuated PMVEC-derived ROS production,
indicating that PKCd is a signaling component upstream of210NOX required for IL-1bemediated ROS production in
PMVECs.
Discussion
Our present results demonstrate that PKCd is an important
regulator of the acute inﬂammatory response in the lung, in
part through the control of neutrophil inﬁltration and acti-
vation. IT administration of a PKCd inhibitor protected
the lung from sepsis-induced histopathological changes
(Figure 2) and attenuated neutrophil migration, as evidenced
by a signiﬁcant decrease in the inﬂux of MPOþ cells into the
lung (Figure 3). Furthermore, PKCd inhibition attenuated
sepsis-induced expression of the endothelial adhesion mol-
ecules ICAM-1 and VCAM-1 in the lungs of CLP septic rats
(Figures 3 and 4), suggesting a role for PKCd in the regula-
tion of neutrophileendothelial cell interaction. Importantly
for clinical translation, the present results demonstrate that IT
delivery (across the lung epithelium) of the PKCd inhibitor
coupled to a protein transduction domain (TAT) facilitates
distribution within the lung parenchyma (Figure 1), including
pulmonary endothelial cells, thus validating the feasibility of
modulating the pulmonary endothelium without the need for
systemic infusion (which would likely result in more wide-
spread distribution of the inhibitor).
The speciﬁc mechanisms involved in neutrophil recruit-
ment to the lung during indirect pulmonary injury have yet
to be clearly deﬁned, but they likely involve unique organ-
speciﬁc pathways.56 In contrast to most organs, in which
neutrophil accumulation is mediated through postcapillary
venules, in the lung neutrophil migration occurs principally
across the capillary endothelium.2,37,45,57 Although the
extensive pulmonary capillary system creates a physical trap
for neutrophil sequestration, vascular inﬂammation is a
critical aspect of indirect pulmonary injury that promotes
neutrophil inﬂux.9,12,58 Although the proinﬂammatory
signaling role of PKCd in endothelial cells and neutrophils
has been described in a variety of experimental systems,59
the speciﬁc role of PKCd in pulmonary endothelial cells
in response to indirect pulmonary injury is not known.
In the lung, neutrophil recruitment involves both integrin-
dependent and integrin-independent pathways.37,43,45,60,61
Although both pathways may function simultaneously, the
relative importance of a speciﬁc pathway is stimulus-
dependent.37,45 Integrin-dependent neutrophil recruitment to
the lung involves neutrophil b2- and b1-integrins and their
endothelial binding partners ICAM-1 and VCAM-1,
respectively.7,32,62e64 Lung ICAM-1 and VCAM-1 are up-
regulated in patients with ARDS and in animal models of
lung injury.2,65,66 In sepsis and other diseases with systemic
inﬂammation, VCAM-1emediated neutrophil recruitment to
the lung is increased through enhanced neutrophil expression
of b1-integrins, such as a4b1.
6,67 We observed a consistent
increase in endothelium ICAM-1 and VCAM-1 expression in
CLP septic rat lungs, and this critical component of the in-
ﬂammatory response was attenuated on PKCd inhibitionajp.amjpathol.org - The American Journal of Pathology
PKCd Regulates Neutrophil Migrationthroughout the arterial, venous, and capillary compartments
of the pulmonary endothelium (Figures 3 and 4). Of crucial
importance is the observation that PKCd inhibition attenuates
pulmonary expression of these adhesion molecules in the
setting of sepsis, an event associated with decreased inﬂux of
MPOþ cells (Figure 3). This establishes a link between PKCd
and up-regulation of proinﬂammatory adhesion molecules in
the injured lung, suggesting a potential mechanism for
reduced neutrophil inﬂux and lung protection.
To identify the critical site or sites of PKCd regulation,
we next examined human neutrophil migration across pri-
mary human PMVEC monolayers. Importantly, in our
in vitro transmigration model only endothelial cell PKCd
was inhibited, thereby permitting delineation of the relative
contribution of endothelial PKCd in modulating neutrophil
migration. A key observation in the present study is the
ﬁnding that endothelial PKCd involvement in neutrophil
transmigration is selective and stimulus-dependent. Specif-
ically, PKCd is an important regulator of integrin-dependent
neutrophil transmigration, a process involving interactions
with ICAM-1 and VCAM-1. In vitro, neutrophil trans-
migration through IL-1beactivated endothelium or in
response to fMLP is dependent on interactions with these
adhesion molecules.37,43e45,57,68 In contrast, integrin-
independent transmigration (speciﬁcally, IL-8emediated
migration) does not require interactions with ICAM-1,
VCAM-1, or PECAM-143e45,60 and, as shown in the pre-
sent study, it is also PKCd independent.
In vivo, inhibition of PKCd resulted in decreased
expression of ICAM-1 and VCAM-1 in the lungs of CLP
septic animals, and in vitro studies demonstrated a direct
role for PKCd in the regulation of VCAM-1 and ICAM-1
expression. Similarly, a regulatory role for PKCd in the
regulation of VCAM-1 and ICAM-1 expression has been
reported in HUVECs and in epithelial cells,25,47,48,50 sug-
gesting that PKCd regulates common proinﬂammatory
signaling pathways in these different cell types. In contrast
to its role in VCAM-1 and ICAM-1 expression, PKCd is not
a regulator of PECAM-1 expression in PMVECs. Thus,
PKCd is not a global regulator of adhesion molecule
expression in the endothelium; rather, this kinase regulates
speciﬁc proinﬂammatory signaling pathways. Taken
together, these in vitro ﬁndings support the hypothesis that
decreased expression of proinﬂammatory adhesion mole-
cules ICAM-1 and VCAM-1 in the pulmonary endothelium,
and the consequently reduced neutrophil inﬂux into the
lung, is a potential mechanism of lung protection on PKCd
inhibition in the setting of sepsis in vivo. Although our
in vitro studies identiﬁed a critical role for PKCd in regu-
lating adhesion molecules, these studies did not rule out
other possible lung-protective effects of PKCd inhibition
in vivo (such as direct effects on neutrophils, alveolar
macrophages, or epithelial and stromal cells) that may also
affect neutrophil migration into the lung during sepsis.59
In endothelial cells, ROS are implicated as important
regulators of NF-kB and the expression of VCAM-1 andThe American Journal of Pathology - ajp.amjpathol.orgICAM-1.53,69e71 IL-1b activation of NF-kB in the endo-
thelium is mediated via the IL-1R1 receptor and is depen-
dent on receptor endocytosis and endosomal ROS
production.53,69,71 Our present ﬁndings indicate that, in
PMVECs, PKCd is a key regulator of ROS production in
response to IL-1b. Furthermore, we have demonstrated that
ROS production in PMVECs is required for both NF-kB
activation and adhesion molecule expression. Although we
cannot rule out effects on other transcription factors, such as
AP-1 or PKCd-dependent post-translational modiﬁcations,50
our ﬁndings indicate that PKCd has an important role in the
up-regulation of ICAM-1 and VCAM-1 in response to
proinﬂammatory cytokines in a deﬁned, human cell-based
in vitro system. Furthermore, pathophysiological improve-
ments in CLP septic rat lungs corresponded to decreased
ICAM-1 and VCAM-1 levels on PKCd inhibition in vivo,
suggesting an evolutionarily conserved and therefore
potentially clinically relevant mechanism.
In summary, our ﬁndings implicate PKCd as a key re-
gulator of pulmonary endothelial adhesion molecule expres-
sion and the inﬂux of neutrophils in response to systemic
sepsis and indirect pulmonary injury. Of clinical import, the
up-regulation of adhesion molecules in response to inﬂam-
matory activation can be attenuated by inhibiting PKCd
in both rodents and primary human cells, an approach that
resulted in signiﬁcant lung protection in vivo in the setting of
sepsis. It is therefore tempting to speculate that selective
delivery of PKCd inhibitors to the lung could modulate
aberrant neutrophileendothelial cell interactions during acute
inﬂammation, but without producing global immunosup-
pression (given that we observed selective and stimulus-
speciﬁc roles of PKCd during inﬂammatory signaling). In
conclusion, the present ﬁndings suggest that targeting pul-
monary PKCd activitymay offer a unique therapeutic strategy
to regulate neutrophil migration and activation in sepsis-
induced pulmonary dysfunction and ARDS.24,72
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